To order this detailed 600+ page report, please visit this - https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html
Key Inclusions
§
A detailed assessment
of the current market landscape of ADCs, providing information on drug
developer(s) and technology provider(s), phase of development (marketed,
clinical and preclinical / discovery stage) of lead candidates, target antigen,
type of linker, type of payload / warhead / cytotoxin, type of antibody,
antibody origin, antibody isotype, type of therapy (monotherapy and combination
therapy), combination drug (if being evaluated as combination therapy), target
indication(s), line of treatment, route of administration and dosing frequency.
§
Elaborate profiles of
the clinical stage companies (shortlisted based on phase of development of the
lead drug) and their respective product portfolios; each profile features an
overview of the company, its financial information (if available), detailed
information on advanced stage pipeline candidates (featuring a drug overview,
clinical development plan and key clinical trial results) and an informed
future outlook.
§
An analysis of the
key promotional strategies that have been adopted by the developers of marketed
products, namely POLIVY™, LUMOXITI™, BESPONSA®, MYLOTARG™, KADCYLA® and
ADCETRIS®.
§
An assessment of the
various therapeutics that are being evaluated in combination with ADCs. The
study also presents the likely evolution of these therapeutics across different
indications.
§
A review of the
evolution of ADC conjugation technologies, highlighting the various approaches
that have been adopted across different generations; in addition, it presents a
review of the existing competition between various conjugation approaches that
are available / under development.
§
An overview of the
studies conducted to better analyze non-clinical data and support
first-in-human (FIH) dose selection in ADCs. The study presents findings from
various ADC studies in different animal models. It also includes an analysis of
the different methods used in estimating FIH doses. In addition, it highlights
the possible FIH starting doses and estimated dose escalations required to
reach human maximum tolerated dose (MTD).
§
An elaborate
discussion on various factors that form the basis for the pricing of ADC
products, featuring different models / approaches that pharmaceutical companies
may choose to adopt while deciding the price of their respective lead therapy
candidates that are likely to be marketed in the coming years.
§
A case study on
manufacturing of ADCs, highlighting the key challenges, and a list of contract
service providers that are involved in this domain.
§
A case study on
companies offering companion diagnostics that can potentially be used to make
treatment related decisions involving ADCs, providing information on the
geographical location of key diagnostic developers, affiliated disease
biomarkers, assay technique involved, target indication(s), the type of sample
required (tumor tissue, blood, bone marrow and others) and the drug candidates
for which a particular test was developed.
The report also features the likely
distribution of the current and forecasted opportunity across important market
segments, mentioned below:
§ Type
of Payload
§ MMAE
§ DM4
§ Camptothecin
§ DM1
§ MMAF
§ Others
§
Type of Linker
§
VC
§
Sulfo-SPDB
§
SMCC
§
VA
§
Hydrazone
§
Others
§ Target
Indication
§ Breast cancer
§ Lymphoma
§ Leukemia
§ Urothelial cancer
§ Lung cancer
§ Ovarian cancer
§ Others
§ Target
Antigen
§
CD30
§
HER2
§
CD22
§
CD33
§
Others
§ Technology
Providers
§
Seattle Genetics
§
ImmunoGen
§
StemCentRx
§
Immunomedics
§
Others
§ Key
Geographical Regions
§ North
America
§ Europe
§ Asia
Pacific
Transcripts of interviews held with the
following senior level representatives of stakeholder companies:
§
Alan Burnett (Professor, School of Medicine, Cardiff
University)
§
Aldo Braca (President and Chief Executive Officer) and
Giorgio Salciarini (Technical Business Development Senior Manager, BSP
Pharmaceuticals)
§
Anthony DeBoer (Director, Business Development, Synaffix)
§
Christian Bailly (Director of CDMO, Pierre Fabre)
§
Christian Rohlff, (Chief Executive Officer and Founder, Oxford
BioTherapeutics)
§
Denis Angioletti (Chief Commercial Officer, Cerbios-Pharma)
§
John Burt (Chief Executive Officer, Abzena)
§
Jennifer L. Mitcham (Director, SMARTag ADCs and
Bioconjugates) and Stacy McDonald (Group Product Manager, Catalent Pharma
Solutions)
§
Laurent Ducry (Head of Bioconjugates Commercial
Development, Lonza)
§
Mark Wright (Site Head, Piramal Healthcare)
§
Sasha Koniev (Chief Executive Officer & Co-Founder, Syndivia)
§
Tatsuya Okuzumi (Associate General Manager, Ajinomoto
Bio-Pharma Services)
§
Toshimitsu Uenaka (Executive Director) and Takashi Owa
(Chief Innovation Officer, Eisai)
§
Wouter Verhoeven (Chief Business Officer, NBE-Therapeutics)
To request sample pages, please visit this -
https://www.rootsanalysis.com/reports/270/request-sample.html
Key Questions Answered
§
Who are the leading industry and non-industry players engaged
in this market?
§
Who are the key ADC development and manufacturing technology
providers?
§
What are the prevalent and upcoming trends related to ADC
payload and linkers?
§
What are the new biologic target antigens being explored
for ADC development?
§
Who are the key / emerging CMOs, in different regions, that
you can reach out to for your manufacturing requirements?
§
Who are the key investors in the ADC market?
§
What are the most prominent drugs / therapies being
currently used in combination with ADCs?
§
What kind of partnership models are commonly adopted by ADC
developers / manufacturers?
§
Who are the key opinion leaders / experts who can support
contemporary ADC development efforts?
§
How is the current and future market opportunity likely to
be distributed across key market segments?
§
What kind of commercialization and promotional strategies
are being used by ADC developers?
§
You may also be interested in the following titles:
1.
ADC Contract
Manufacturing Market
(3rd Edition), 2018-2030
2.
Gene Therapy Market (3rd Edition), 2019 -
2030
3.
Global T-Cell (CAR-T,
TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030
Contact Us
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
